OLI Technologies
PrivateLast Round
Seed
Jun 3, 2025
Momentum Score
50 /100
Company Overview
OLI Technologies is a medical device company that is developing a portable hemodialysis system for end-stage kidney patients.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Health IoT
Business Model
B2B
Customer Profile
Hardware + Subscription, Hardware Sales, Services & Consulting
AI Layer
Non-AI
Keywords
portable hemodialysishome hemodialysisportable dialysissorbent technologyend-stage kidney diseasekidney dialysismedical deviceend-stage renal diseaseESRDdialysis at homerenal carekidney failure treatment
Historical Pricing
Historical view of private secondary pricing and transaction trends.
OLI Technologies Comps
Public and private peers based on sector, stage, and business model.
OLI Technologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jun 3, 2025 |
Key People
Founding team and executive leadership
OLI Technologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Verge HealthTech Fund | Seed |
| SOSV | Seed |
OLI Technologies Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about OLI Technologies's valuation, stock price, and market status.
Firmographic Details
HeadquartersNew Jersey
Employee Range8
Year Founded2021
Last FundingJun 3, 2025